ArticleCancer cell2021
Molecular classification and diagnostics of upper urinary tract urothelial carcinoma.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
116citing papers in PubMed, 2 pooled it
24.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
116 citing papers in PubMed, 2 syntheses or guidelines pooled it, 160 citations in OpenAlex.
- The efficacy of neoadjuvant therapy for upper tract urothelial carcinoma: a systematic review and meta-analysis.BMC cancer · 2025Pooled it
- Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment.Journal for immunotherapy of cancer · 2023Pooled it
- Segmental ureterectomy versus radical nephroureterectomy for middle and distal ureteral tumors associated with hydronephrosis: a comparative analysis of oncological outcomes and postoperative renal function.International urology and nephrology · 2026Article
- Integrating Molecular Classification Based on FGFR3, KRAS, HRAS, and TP53 Mutation With TNM Staging Modestly Improves Prediction of Prognosis of Upper Tract Urothelial Carcinoma After Surgery.International journal of urology : official journal of the Japanese Urological Association · 2026Article
- Extrachromosomal DNA in urothelial carcinoma: mechanisms and clinical applications.Nature reviews. Urology · 2026Review
- SPP1-driven spatial niche remodelling defines aggressive progression in the basal subtype of upper tract urothelial carcinoma.Clinical and translational medicine · 2026Article
- Upper Tract Urothelial Carcinoma: Molecular Pathogenesis and Current Treatment Strategies-A Narrative Review.Cancers · 2026Review
- Modern management of locally advanced urothelial carcinoma of the upper urinary tract.World journal of urology · 2026Review
- Genomic Characterization of Urothelial Carcinoma and Sarcomatoid Carcinoma of the Upper Urinary Tract.Cancers · 2026Article
- OncogenicJournal for immunotherapy of cancer · 2026Article
- SOX2-positive upper tract urothelial carcinoma: Clinicopathological characteristics and therapeutic implications.Oncology letters · 2026Article
- A perioperative multi-modal fusion and deep learning-based prognostic system for upper tract urothelial carcinoma: a multi-institutional study.Insights into imaging · 2026Article
- Nectin-4 expression in upper and lower tract urothelial carcinoma: correlation with early-stage disease and prognostic relevance.Virchows Archiv : an international journal of pathology · 2026Article
- Enhancer and metabolic rewiring by KMT2C-COMPASS or KMT2D-COMPASS family loss in cancer creates druggable vulnerabilities.Nature reviews. Cancer · 2026Review
- Comprehensive Genomic Characterization Between Urothelial Carcinoma Subtypes/Divergent Differentiation (S/DD) and Pure Urothelial Carcinoma Using a Large-Scale Japanese Genomic Panel Dataset.International journal of urology : official journal of the Japanese Urological Association · 2026Observational
- High Sensitivity ctDNA Analysis Using a Novel Panel and NOIR-SS Technology for Monitoring Advanced Urothelial Carcinoma.Cancer medicine · 2026Article
- Proteome profiles of esophageal squamous cell carcinoma tie mitochondrial complex I to immunotherapy.EMBO molecular medicine · 2026Article
- Performance of Urine Fluorescence In Situ Hybridization for Diagnosis of Upper Tract Urothelial Carcinoma: A Comprehensive Review.International journal of molecular sciences · 2026Review
- Stage-dependent prognostic impact of GATA3/FOXA1-defined luminal-like subtype in upper tract urothelial carcinoma.Virchows Archiv : an international journal of pathology · 2026Article
- The tumor-associated fibroblasts regulate urothelial carcinoma progression.Journal of molecular cell biology · 2026Article
56 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
38 authors at 7 institutions in 4 countries.
Yoichi FujiiDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto 606-8501, Japan; Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto 606-8501, Japan; Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
Yusuke SatoDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto 606-8501, Japan; Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
Hiromichi SuzukiDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto 606-8501, Japan.
Nobuyuki KakiuchiDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto 606-8501, Japan; Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto 606-8501, Japan.
Tetsuichi YoshizatoDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto 606-8501, Japan.
Andrew T LenisUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Shigekatsu MaekawaDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
Akira YokoyamaDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto 606-8501, Japan.
Yasuhide TakeuchiDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto 606-8501, Japan; Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto 606-8501, Japan.
Yoshikage InoueDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto 606-8501, Japan; Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto 606-8501, Japan.
Yotaro OchiDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto 606-8501, Japan.
Yusuke ShiozawaDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto 606-8501, Japan.
Kosuke AokiDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto 606-8501, Japan.
Kenichi YoshidaDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto 606-8501, Japan.
Keisuke KataokaDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto 606-8501, Japan; Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo 104-0045, Japan.
Masahiro M NakagawaDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto 606-8501, Japan.
Yasuhito NannyaDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto 606-8501, Japan; Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto 606-8501, Japan.
Hideki MakishimaDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto 606-8501, Japan; Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto 606-8501, Japan.
Jimpei MiyakawaDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
Taketo KawaiDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
Teppei MorikawaDepartment of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
Yuichi ShiraishiLaboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Kenichi ChibaLaboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Hiroko TanakaLaboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Genta NagaeGenome Science Division, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo 153-8904, Japan.
Masashi SanadaDepartment of Advanced Diagnosis, Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya 460-0001, Japan.
Eiji SugiharaResearch and Development Center for Precision Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8550, Japan.
Taka-Aki SatoResearch and Development Center for Precision Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8550, Japan.
Tohru NakagawaDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan; Department of Urology, Teikyo University School of Medicine, Tokyo 173-8606, Japan.
Masashi FukayamaDepartment of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
Tetsuo UshikuDepartment of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
Hiroyuki AburataniGenome Science Division, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo 153-8904, Japan.
Satoru MiyanoLaboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan; Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Jonathan A ColemanUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yukio HommaDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan; Department of Urology, Japanese Red Cross Medical Center, Tokyo 150-8935, Japan.
David B SolitHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Haruki KumeDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
Seishi OgawaDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto 606-8501, Japan; Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto 606-8501, Japan; Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm 17177, Sweden. Electronic address: sogawa-tky@umin.ac.jp.
Kyoto University · JPThe University of Tokyo · JPMemorial Sloan Kettering Cancer Center · USUniversity of Tsukuba · JPJapanese Red Cross Medical Center · JPNational Hospital Organization · JPTokyo Medical University · JP
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MSPORE in Bladder CancerP50CA221745 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI OSTROVNAYA, IRINA · 2018 to 2024
$11.8MProject 3: Modeling tumor evolution and drug response in bladder cancer organoidsP01CA221757 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SHEN, MICHAEL M. · 2018 to 2022
$8.6MUROLOGY ONCOLOGY RESEARCH TRAINING GRANTT32CA082088 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Brett Stewart Carver · 1999 to 2026
$7.1MNCI NIH HHS P01 CA221757NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA221745NCI NIH HHS T32 CA082088
Abstract
Upper urinary tract urothelial carcinoma (UTUC) is one of the common urothelial cancers. Its molecular pathogenesis, however, is poorly understood, with no useful biomarkers available for accurate diagnosis and molecular classification. Through an integrated genetic study involving 199 UTUC samples, we delineate the landscape of genetic alterations in UTUC enabling genetic/molecular classification. According to the mutational status of TP53, MDM2, RAS, and FGFR3, UTUC is classified into five subtypes having discrete profiles of gene expression, tumor location/histology, and clinical outcome, which is largely recapitulated in an independent UTUC cohort. Sequencing of urine sediment-derived DNA has a high diagnostic value for UTUC with 82.2% sensitivity and 100% specificity. These results provide a solid basis for better diagnosis and management of UTUC.
Indexed as
AgedBiomarkers, TumorCarcinoma, Transitional CellDNA MethylationFemaleGene DosageGene Expression Regulation, NeoplasticHumansMaleMiddle AgedMutationPolymorphism, Single NucleotideProto-Oncogene Proteins c-mdm2ras ProteinsReceptor, Fibroblast Growth Factor, Type 3Tumor Suppressor Protein p53Biomarkers, TumorFGFR3 protein, humanMDM2 protein, humanProto-Oncogene Proteins c-mdm2ras ProteinsReceptor, Fibroblast Growth Factor, Type 3TP53 protein, humanTumor Suppressor Protein p53FGFR3hypermutationintegrated molecular studymolecular classificationmolecular diagnosticRASTP53transcriptomeupper urinary tract urothelial carcinomaurothelial carcinoma
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.